Hypertension in Kidney Disease

Hypertension in Kidney Disease

Hypertension in Kidney Disease

On this page

Pathophysiology in CKD HTN - Pressure Cooker Kidneys

Kidneys in CKD struggle to manage fluid and blood pressure, acting like overloaded pressure cookers.

  • Core Mechanisms:
    • Volume Expansion: ↓ GFR → Impaired $Na^{+}$ & $H_{2}O$ excretion → ↑ Extracellular fluid → ↑ Cardiac output.
    • RAAS Upregulation: Renal hypoperfusion/ischemia → ↑ Renin → ↑ $Ang ext{ II}$ (vasoconstrictor) & Aldosterone ($Na^{+}$ retention).
    • Sympathetic Nervous System (SNS) Overdrive: Afferent signals from diseased kidneys stimulate central SNS.
    • Endothelial Dysfunction: ↓ Nitric Oxide ($NO$), ↑ Endothelin-1 → Impaired vasodilation & pro-inflammatory state.
  • Consequences: Systemic vasoconstriction, increased vascular resistance, and arterial stiffness.

⭐ Nocturnal hypertension (loss of normal nighttime BP dip) is a hallmark in CKD, strongly predicting cardiovascular events and faster kidney disease progression.

Diagnosis of CKD HTN - Sizing Up Pressure

  • BP Measurement Methods:
    • Standardized Office BP (SOBP): Baseline, multiple readings.
    • Ambulatory BP Monitoring (ABPM): Gold standard; detects white-coat/masked HTN, nocturnal patterns (non-dipping).
    • Home BP Monitoring (HBPM): Valid alternative for diagnosis & ongoing monitoring.
  • Diagnostic Criteria (HTN in CKD):
    • SOBP: ≥130/80 mmHg.
    • ABPM (24h avg): ≥130/80 mmHg.
    • HBPM (avg over ≥1 week): ≥130/80 mmHg.
  • KDIGO 2021 Target: Aim for SBP <120 mmHg (using standardized office BP), if tolerated.

⭐ ABPM is superior in CKD for diagnosis and prognosis, especially by identifying non-dipping patterns (absent nocturnal BP fall of 10-20%), which are linked to significantly increased cardiovascular risk and faster CKD progression.

Management of CKD HTN - Deflating Pressure

BP Target: <130/80 mmHg. Consider <120 mmHg SBP if tolerated (high-risk).

1. Lifestyle Modifications (LSM):

  • Salt: <2 g/day Na (or <5 g/day NaCl)
  • Weight: Target BMI <25 kg/m²
  • DASH diet (monitor K+)
  • Exercise: ≥150 min/week
  • Limit alcohol

2. Pharmacotherapy:

  • First-line: ACE inhibitors (ACEi) or ARBs
    • Preferred if albuminuria >30 mg/day (ACR >3 mg/mmol)
    • Monitor SCr (↑ up to 30% acceptable) & K+.
    • ⚠️ Avoid: Bilateral renal artery stenosis, angioedema.
  • Add-on therapy:
    • Diuretics: Thiazides (eGFR ≥30 mL/min/1.73m²), Loops (eGFR <30 mL/min/1.73m² / overload).
    • CCBs (Dihydropyridines e.g., Amlodipine).
    • MRAs (e.g., Finerenone, Spironolactone) if eGFR/K+ allow, esp. with albuminuria.
    • Beta-blockers (if compelling indication e.g., CAD, HFrEF).

⭐ ACEi/ARBs are vital in proteinuric CKD for renoprotection via ↓ intraglomerular pressure & proteinuria, beyond BP reduction.

Special CKD HTN Cases - Tricky Pressure Points

  • Resistant HTN: BP >140/90 mmHg on ≥3 drugs (incl. diuretic). Rule out pseudo-resistance. Maximize diuretics, add MRA (spironolactone/eplerenone), then others.
  • ADPKD: Early HTN. ACEi/ARB first-line. Target BP <130/80 mmHg; consider <110/75 mmHg if young (HALT-PKD trial).
  • Glomerulonephritis (GN): Volume & RAAS driven. ACEi/ARB for BP & proteinuria. Loop diuretics for volume control.
  • Post-Transplant HTN: Multifactorial (CNIs, steroids). CCBs (e.g., amlodipine) often initial choice. ACEi/ARB cautiously (monitor K+, GFR).

⭐ In ADPKD, rigorous BP control with ACEi/ARB can slow cyst growth and GFR decline, a key finding from the HALT-PKD trial supporting aggressive targets in select patients (e.g., younger, preserved GFR).

High‑Yield Points - ⚡ Biggest Takeaways

  • Chronic Kidney Disease (CKD) is the most common cause of secondary hypertension.
  • Target Blood Pressure (BP) in most CKD patients is <130/80 mmHg.
  • ACE inhibitors (ACEi) or Angiotensin II Receptor Blockers (ARBs) are first-line agents, especially with proteinuria.
  • Monitor for hyperkalemia and an initial ↑ in serum creatinine with ACEi/ARBs.
  • Renal artery stenosis is a significant cause of renovascular hypertension; screen if suspected.
  • Sodium and water retention (volume overload) is a major pathogenic factor in CKD-associated hypertension.
  • Lifestyle modifications, including strict salt restriction, are fundamental in management.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Hypertension in Kidney Disease

Test your understanding with these related questions

A hypertensive diabetic patient with microalbuminuria should receive:

1 of 5

Flashcards: Hypertension in Kidney Disease

1/10

The screening investigation used in renovascular hypertension is _____

TAP TO REVEAL ANSWER

The screening investigation used in renovascular hypertension is _____

Captopril DTPA

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free